Swiss National Bank’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Swiss National Bank’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24,700	Closed	-$161K	–	2544
2018 Q3	$161K	Hold	24,700	–	–	﹤0.01%	2502
2018 Q2	$189K	Hold	24,700	–	–	﹤0.01%	2523
2018 Q1	$552K	Hold	24,700	–	–	﹤0.01%	2342
2017 Q4	$315K	Buy	24,700 +11,300	+84%	+$166K	﹤0.01%	2485
2017 Q3	$209K	Hold	13,400	–	–	﹤0.01%	2515
2017 Q2	$188K	Buy	+13,400	New	+$287K	﹤0.01%	2553

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Swiss National Bank's JNCE Position: Q4 2018 in Review

Swiss National Bank sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2018, closing a stake of 24,700 shares — an estimated $161K sold.

Swiss National Bank first reported a position in JNCE in Q2 2017 and held it in 6 quarters. The position peaked at $552K in Q1 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q4 2018.

Swiss National Bank reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Swiss National Bank sold 24,700 Jounce Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $161K.
Swiss National Bank first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
Swiss National Bank's Jounce Therapeutics, Inc. Common Stock position peaked at $552K in Q1 2018.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Swiss National Bank's 13F filing for Q4 2018, filed 13 Feb 2019.